ArticleFrontiers in veterinary science2025
Oligodendroglioma pseudoprogression after radiotherapy in a dog: a case report.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudoprogression is a clinical and imaging phenomenon characterized by an increase in the size and contrast enhancement pattern of a glioma lesion following treatment with radiotherapy. In human beings, a substantial body of literature describes the phenomenon of pseudoprogression in glioblastoma after radiotherapy. The occurrence of gliomas in the cranial nerves has been reported in human beings as a clinically rare entity. A 7-year-old spayed female French Bulldog was presented with left-sided craniofacial muscle atrophy for a duration of 3 months and episodes of compulsive circling to the left. After a neurological examination, a magnetic resonance (MR) imaging scan of the brain was performed. A T2-and T2 FLAIR-weighted hyperintense, non-contrast-enhancing, T1-weighted hypointense intra-axial suprasellar lesion was found. In addition, an extra-axial, T1-weighted hyperintense, contrast-enhancing mass was identified at the level of the left trigeminal nerve. The lesions were presumptively diagnosed as a glioma and a left trigeminal nerve sheath tumor based on their imaging characteristics and the breed of the patient. A course of stereotactic radiotherapy (SRT) was prescribed, and 3 months after treatment, there was significant progression in the size of the suprasellar mass, indicative of either true progression or pseudoprogression. The left trigeminal nerve mass remained stable in size. Treatment with glucocorticoids resulted in a reduction in the size of the suprasellar mass, as observed on MR imaging 7 months after treatment. The left trigeminal nerve mass remained stable in size. Progression in the size of the suprasellar mass and the left trigeminal nerve mass occurred 9 months after the first course of treatment, and a second course of stereotactic radiotherapy was administered. Sixteen months after the first course of radiotherapy, a necropsy was performed. The suprasellar lesion and the left trigeminal nerve lesion were diagnosed as oligodendrogliomas on histopathology. Trigeminal nerve oligodendrogliomas and pseudoprogression following radiotherapy have not been previously described in dogs. Pseudoprogression should be considered a differential diagnosis for the progression of presumed or confirmed glioma lesions after treatment with radiotherapy. Concurrent oligodendroglioma lesions in the trigeminal nerve are also possible and should be included in the list of differential diagnoses for dogs with concurrent brain lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.